Pivotal Trials
From First-in-Human to Proof-of-Concept – Expert Pivotal Trials Solutions
At GCP ClinPlus, we specialize in the design and execution of pivotal clinical studies that support global regulatory approvals. With over 22 years of experience, over 2,200 trials conducted, and 210+ drug and device approvals, we are a trusted CRO partner for China Phase II CRO/III registrational trials across China. Our integrated services, deep regulatory knowledge, and long-standing partnerships with top investigators and research hospitals ensure efficient patient enrollment, global-standard data, and strong compliance with FDA, EMA, and NMPA expectations. Whether part of a global multi-regional clinical trial (MRCT) or a standalone China registration study, we deliver quality, speed, and confidence.
Your Gateway to Global Development – Integrated Pivotal Trials Services
Pivotal studies—often Phase II/China Phase III CRO confirmatory trials—are the cornerstone of regulatory submission packages and commercialization strategies. These large-scale, high-stakes studies must be executed with scientific rigor, operational precision, and regulatory alignment.
GCP ClinPlus is uniquely positioned to support these trials through our:
Full-service clinical capabilities from study design and regulatory strategy to trial conduct, data analysis, and submission support
22+ years of operational experience, including over 1,100 Phase II/III studies, and a 100% audit pass rate
Broad therapeutic coverage, particularly in oncology, endocrinology, autoimmune, infectious disease, ophthalmology, and cell/gene therapies
We provide:
Regulatory consulting and IND/NDA preparation
Investigator and site selection with access to >80% of specialty hospitals in key areas
Medical monitoring, PV, and real-time safety reporting
Robust patient recruitment strategies with dedicated enrollment teams
GCP-compliant data management, statistical analysis, and submission-ready reporting
With our strong relationships across clinical sites and experience navigating China's evolving regulatory landscape, we help sponsors achieve rapid enrollment, protocol adherence, and data integrity. Our medical and statistical leaders have successfully supported over 120 global filings and 70 regulatory review defenses in China and internationally.
Whether you're running a China-only pivotal trial or integrating China into a global MRCT, GCP ClinPlus provides the expertise and operational muscle to execute flawlessly and deliver globally accepted results.
Why Sponsors Choose GCP ClinPlus for Pivotal Trials in China
Proven Success: 1,100+ pivotal Phase II/III studies conducted with 210+ approvals.
Regulatory Expertise: Deep knowledge of FDA, EMA, and NMPA pathways.
Rapid Enrollment: Access to China's largest hospitals and streamlined site activation.
Global-Standard Data Quality: 100% sponsor and regulatory audit pass rate.
Scientific Leadership: MDs, PhDs, and ex-regulatory experts leading project teams.
End-to-End Execution: Seamless integration across clinical, regulatory, biometrics, and PV.
Flexible Models: Support for both standalone China trials and global MRCTs.
Client-Centric: Focused on transparency, speed, and long-term partnership success.
For more information about clinical trial research design, please feel free to contact us!
